Signs and Symptoms, Evaluation, and Management of Genitourinary Tract Consequences of Premature Ovarian Insufficiency

Overview

Journal Prz Menopauzalny

Publisher Termedia

Date 2018 Oct 26

PMID 30357024

Citations 2

Authors

Anna Calik-Ksepka

Monika Grymowicz

Ewa Rudnicka

Jolanta Skorska

Paulina Machura

Wojciech Pieta

Roman Smolarczyk

Affiliations

Soon will be listed here.

Abstract

Premature ovarian insufficiency (POI) occurs in 1% of women under 40 years old. Hypoestrogenism associated with this condition may result in vaginal atrophy and urine incontinence, called genitourinary syndrome. The symptoms include: vaginal dryness, irritation, dyspareunia, and dysuria. There is relative lack of studies on the occurrence and treatment of genitourinary problems in women with POI. Prevalence rates vary from 17 to 54% depending on cause, duration of oestrogen depletion, and the treatment used. Patients with POI gain lower scores in tests measuring vaginal health or sexual function in comparison to healthy peers. Hormonal treatment in premature ovarian insufficiency is recommended until the natural age of menopause. The vaginal route of oestrogen administration is supposed to be the criterion standard in treating genitourinary symptoms. Androgen supplementation is not routinely recommended.

Citing Articles

Primary ovarian insufficiency: update on clinical and genetic findings.

Federici S, Rossetti R, Moleri S, Munari E, Frixou M, Bonomi M Front Endocrinol (Lausanne). 2024; 15:1464803.

PMID: 39391877 PMC: 11466302. DOI: 10.3389/fendo.2024.1464803.

Li X, Li P, Liu Y, Yang H, He L, Fang Y Qual Life Res. 2019; 29(1):19-36.

PMID: 31620985 PMC: 6962283. DOI: 10.1007/s11136-019-02326-2.

References

Yela D, Soares P, Benetti-Pinto C . Influence of Sexual Function on the Social Relations and Quality of Life of Women with Premature Ovarian Insufficiency. Rev Bras Ginecol Obstet. 2018; 40(2):66-71. PMC: 10316931. DOI: 10.1055/s-0037-1615289. View

Orshan S, Furniss K, Forst C, Santoro N . The lived experience of premature ovarian failure. J Obstet Gynecol Neonatal Nurs. 2001; 30(2):202-8. DOI: 10.1111/j.1552-6909.2001.tb01536.x. View

Karram M, Yeko T, Sauer M, Bhatia N . Urodynamic changes following hormonal replacement therapy in women with premature ovarian failure. Obstet Gynecol. 1989; 74(2):208-11. View

Leining M, Gelber S, Rosenberg R, Przypyszny M, Winer E, Partridge A . Menopausal-type symptoms in young breast cancer survivors. Ann Oncol. 2006; 17(12):1777-82. DOI: 10.1093/annonc/mdl299. View

Kokot-Kierepa M, Bartuzi A, Kulik-Rechberger B, Rechberger T . [Local estrogen therapy--clinical implications--2012 update]. Ginekol Pol. 2013; 83(10):772-7. View

Skouby S, Al-Azzawi F, Barlow D, Calaf-Alsina Erdogan Ertungealp J, Gompel A, Graziottin A . Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas. 2005; 51(1):8-14. DOI: 10.1016/j.maturitas.2005.02.019. View

Graziottin A . Menopause and sexuality: key issues in premature menopause and beyond. Ann N Y Acad Sci. 2010; 1205:254-61. DOI: 10.1111/j.1749-6632.2010.05680.x. View

Benetti-Pinto C, Soares P, Giraldo H, Yela D . Role of the different sexuality domains on the sexual function of women with premature ovarian failure. J Sex Med. 2014; 12(3):685-9. DOI: 10.1111/jsm.12743. View

Palacios S, Mejia A, Neyro J . Treatment of the genitourinary syndrome of menopause. Climacteric. 2015; 18 Suppl 1:23-9. DOI: 10.3109/13697137.2015.1079100. View

10.

Benetti-Pinto C, Giraldo P, Pacello P, Soares P, Yela D . Vaginal epithelium and microflora characteristics in women with premature ovarian failure under hormone therapy compared to healthy women. Arch Gynecol Obstet. 2015; 292(1):159-64. DOI: 10.1007/s00404-015-3616-2. View

11.

Madalinska J, van Beurden M, Bleiker E, Valdimarsdottir H, Hollenstein J, Massuger L . The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol. 2006; 24(22):3576-82. DOI: 10.1200/JCO.2005.05.1896. View

12.

Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B . Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016; 215(6):704-711. DOI: 10.1016/j.ajog.2016.07.045. View

13.

Rafique S, Sterling E, Nelson L . A new approach to primary ovarian insufficiency. Obstet Gynecol Clin North Am. 2012; 39(4):567-86. PMC: 3727655. DOI: 10.1016/j.ogc.2012.09.007. View

14.

Bachmann G, Komi J . Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2009; 17(3):480-6. DOI: 10.1097/gme.0b013e3181c1ac01. View

15.

Pacello P, Yela D, Rabelo S, Giraldo P, Benetti-Pinto C . Dyspareunia and lubrication in premature ovarian failure using hormonal therapy and vaginal health. Climacteric. 2013; 17(4):342-7. DOI: 10.3109/13697137.2013.860116. View

16.

Suckling J, Lethaby A, Kennedy R . Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006; (4):CD001500. DOI: 10.1002/14651858.CD001500.pub2. View

17.

Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B . ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016; 31(5):926-37. DOI: 10.1093/humrep/dew027. View

18.

Kalantaridou S, Vanderhoof V, Calis K, Corrigan E, Troendle J, Nelson L . Sexual function in young women with spontaneous 46,XX primary ovarian insufficiency. Fertil Steril. 2007; 90(5):1805-11. PMC: 2592535. DOI: 10.1016/j.fertnstert.2007.08.040. View

19.

Pitsouni E, Grigoriadis T, Falagas M, Salvatore S, Athanasiou S . Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas. 2017; 103:78-88. DOI: 10.1016/j.maturitas.2017.06.029. View

20.

Sturdee D, Panay N . Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010; 13(6):509-22. DOI: 10.3109/13697137.2010.522875. View